Director of the Cold Spring Harbor Lab (CSHL) Cancer Center David Tuveson was elected President-Elect of the American Association for Cancer Research (AACR). Tuveson focuses on diagnosing and treating pancreatic cancer in preclinical and clinical settings. Central to his work is a technology to cultivate small, functional pancreatic cancer “organoids” in a dish.
As AACR President-Elect, Tuveson will work with the Board of Directors and the AACR membership, which includes more than 47,000 members in 126 countries. He will officially become President-Elect on April 29, 2020 during the AACR’s Business Meeting of Members and will assume the presidency in April 2021 at the AACR Annual Meeting.
“I am humbly honored to serve our community as the President-Elect of the AACR. AACR’s mission is to improve the lives of people world-wide through supporting cancer research and education, and with AACR’s leadership much exciting progress has been made over the last 50 years,” Tuveson said. “Sadly, however, many patients still suffer and die from cancer, and additional scientific and logistical challenges need to be overcome in order to improve their outcomes. Collectively we can solve the hardest problems and help the most cancer patients.”
“Dr. Tuveson is a highly distinguished physician-scientist whose pioneering pancreatic cancer research has had an enormous impact on our basic understanding and treatment of this deadly disease,” said Margaret Foti, CEO of the AACR. “His scientific and clinical expertise, together with his visionary leadership and dedication to conquering cancer in all its forms, will be invaluable to the AACR as our organization continues to work toward the goal of preventing and curing all cancers.”